Phage Biotechnology Corp. : Company Profile

Company Profile

Phage Biotechnology Corporation (“Phage”) is a Delaware Corporation, incorporated in 1998 and headquartered in San Diego, California. The company has its manufacturing plant in San Diego, and has plans to acquire additional space for quality control adjacent to the manufacturing facility. In addition, the company has a pre-clinical research center in Kiev, Ukraine. The Company was formed to manufacture recombinant protein pharmaceuticals as either “bio-similar” drugs, or as new drug entities.

labpic Phage manufactures protein pharmaceuticals that fall into two classes, including 1) “bio-similar” versions of marketed drugs whose patents have expired, and 2) new drug candidates developed by Phage that will undergo clinical trials, including longer-acting PEGylated versions of marketed protein products. Utilizing a proprietary process, recombinant proteins can be produced relatively rapidly and at low cost utilizing the Phage manufacturing process. This technology is being applied to the production of key protein pharmaceuticals, with multi-billion dollar estimated market values.

As a result of this production advantage, Phage is targeting the production and sale of drugs that no longer have patent protection. The primary method for developing sales will be to offer buyers of these types of drugs a substantial price discount (30-50%) compared to all other pharmaceutical producers. Marketing these drugs at discounted levels will provide Phage with significant profit margins, in large part as a result of the lower costs associated with manufacturing these drugs utilizing the Phage process.

In addition to developing biopharmaceuticals whose patents have expired, Phage is also developing new PEGylated versions of these drugs that should substantially increase the marketplace for these drugs. Most protein drugs must be injected daily, but PEGylated versions of these drugs often go to once-weekly injections due to their much increased half-life in the body’s circulation.

labpic Phage also offers contract manufacturing services to third parties. These services include process development for manufacturing biologics, as well the cGMP manufacturing of proteins to support clinical trials. In addition, a number of companies have approached Phage to inquire about the contract manufacturing of therapeutic phage particles for treatment of cancer and Alzheimer’s disease. As Phage has extensive experience in utilizing live bacteriophage particles in cGMP manufacturing processes, this is a potentially large and attractive new business opportunity for Phage. We are aware of no other licensed GMP manufacturing facility that can produce therapeutic phage particles.

All protein and phage products are manufactured at our cGMP facility in San Diego, California which is licensed by the State of California. Phage is managed by a team that is committed to product quality and integrity and has more than 50 years combined experience in the pharmaceutical and biopharmaceutical areas.

Top